

VioQuest Pharmaceuticals, Inc.  
 Form 4  
 May 01, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**WEISER MICHAEL**

2. Issuer Name and Ticker or Trading Symbol  
**VioQuest Pharmaceuticals, Inc.  
 [VOQP]**

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
**50 WEST 57TH STREET, 15TH FLOOR**  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**03/14/2008**

Director  10% Owner  
 Officer (give title below)  Other (specify below)

**NEW YORK, NY 10019**

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock, \$.001 par value					161,206 <sup>(1)</sup>	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: VioQuest Pharmaceuticals, Inc. - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
Stock Option	\$ 19.6 <sup>(1)</sup>					<sup>(2)</sup> 10/28/2013	Common Stock, \$.001 par value
Warrant	\$ 14.1 <sup>(1)</sup>					10/18/2005 10/18/2010	Common Stock, \$.001 par value
Warrant	\$ 4 <sup>(1)</sup>					06/29/2007 06/29/2012	Common Stock, \$.001 par value
Stock Option	\$ 3.8					<sup>(3)</sup> 07/11/2017	Common Stock
Senior Convertible Promissory Notes	\$ 3.8 <sup>(1)</sup>	03/14/2008		C <sup>(4)</sup>	2,631 <sup>(1)</sup>	06/29/2007 06/29/2009	Series B Convertible Preferred Stock <sup>(2)</sup>
Series B Convertible Preferred Stock	\$ 3.8 <sup>(1)</sup>	03/14/2008		C <sup>(4)</sup>	10.57	03/14/2008 <sup>(5)</sup>	Common Stock, \$.001 par value

## Reporting Owners

### Reporting Owner Name / Address

### Relationships

Director 10% Owner Officer Other

WEISER MICHAEL  
50 WEST 57TH STREET, 15TH FLOOR X  
NEW YORK, NY 10019

## Signatures

/s/ Brian Lenz, as attorney-in-fact 05/01/2008

<sup>(1)</sup>Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Adjusted to reflect a 1-for-10 reverse stock split effective on 4/25/2008.
- (2) The option became exercisable in three equal installments of 4,300 on 10-28-2004, 10-28-2005 and 10-28-2006.
- (3) One-third of the option is immediately exercisable, and the remaining vests in two equal installments on 7/11/08 and 7/11/09.
- (4) Notes were amended on 3/14/08 to provide for conversion to Series B Convertible Preferred Stock and a mandatory conversion took place on that date.
- (5) No expiration date.

### Remarks:

Power of Attorney Form incorporated herein by reference to Exhibit 24.1 to Form 4 filed on 7/13/2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.